An interesting implication from this work is the issue of how mRNAs that harbor unspliced U12-type introns escape from the nucleus (Figure 1) . Normally, incompletely spliced RNAs are retained in the nucleus until they are fully processed or they are targeted for degradation. The fate of a newly spliced RNA is typically determined by the deposition of the exon-junction complex (EJC), which assembles over newly joined exons immediately after splicing and promotes export of correctly spliced RNA. It is possible that the presence of the EJC on multiple spliced U2-type exons in U12-containing RNAs is sufficient to mark it for export. On the other hand, specific factors might exist that recognize the partially spliced U12-type RNAs, prevent their degradation, and facilitate their nuclear export. Interestingly, this situation is akin to the fate of mRNAs that retain intronic sequences as part of their normal alternative splicing but are nevertheless exported.
The results reported by König et al. might also have implications for how we think about the evolution of splicing. The minor spliceosome has an early evolutionary origin (Russell et al., 2006) . U2-type splice junctions are far more degenerate than U12-type junctions, suggesting that U12-exons were at one point dominant and U2-exons evolutionarily derived from them. Although provocative, it raises the question of whether more, or even all, pre-mRNA splicing at one point in time occurred in the cytoplasm. The correct expression of the more complex genes and genomes of higher organisms might have required closer coordination of pre-mRNA splicing and quality control with transcription, therefore favoring migration of the splicing reaction to the cell nucleus. Thus, the discovery of splicing in the cytoplasm provides a glimpse into the distant past, while also opening up a new vista on the future of pre-mRNA splicing.
Lysosomes are acidic intracellular organelles where many proteins, lipids, and other macromolecules are delivered for degradation by lysosomal acid hydrolases. Ever since the discovery of lysosomes by de Duve and colleagues (de Duve et al., 1955) , much of our understanding of how proteins are trafficked to this compartment and how they function has come from studies on a wide range of lysosomal storage diseases. In this family of genetic diseases, defects in the function of the lysosome results in mis-sorting or loss of function of lysosomal proteins with deleterious consequences. In the case of the lysosomal storage disease Inclusion-cell (I-cell) disease, lysosomal dysfunction is caused by secretion of most lysosomal enzymes from the cell. Most lysosomal proteins are tagged with a carbohydrate modification that allows their recognition and transport to the lysosome. In this issue, Reczek et al. (2007) identify a new pathway for protein sorting to the lysosome. They show that β-glucocerebrosidase-the lysosomal enzyme defective in patients with Gaucher disease-is delivered to the lysosome through its interaction with the transmembrane protein LIMP-2.
Lysosomal hydrolases from patients with I-cell disease lack a mannose 6-phosphate carbohydrate modification to their N-linked glycans. This finding led to the identification of a defective phosphodiesterase in I-cell patients that is normally responsible for this modification and the mannose 6-phosphate receptor as the receptor required for sorting the majority of acid hydrolases to lysosomes (reviewed in Kornfeld, 1990 ). This example illustrates how studies on human genetic diseases have played critical roles in our understanding of fundamental cell biology.
Not all soluble lysosomal enzymes are targeted via the mannose 6-phosphate receptor. One of the exceptions is β-glucocerebrosidase (βGC), the enzyme that degrades glycosphingolipids and is defective in patients with Gaucher disease (the most common lysosomal storage disease). Patients with I-cell disease have normal levels of βGC in their lysosomes, suggesting that this protein is targeted to the lysosome by a pathway that is independent of the mannose 6-phosphate receptor. The nature of this route to the lysosome has remained elusive. Adding to the puzzle, βGC, a soluble enzyme with no evident membrane tether, seems to be associated with membranes (Rijnboutt et al., 1991) . Now, a study in this issue from Reczek, Saftig, and colleagues (Reczek et al., 2007) provides an answer: βGC is recognized by the lysosomal membrane protein, LIMP-2, which targets βGC to lysosomes. In the absence of LIMP-2, βGC is no longer effectively packaged and is secreted from the cell.
These authors set out to find a receptor for βGC by examining proteins that interact with βGC. Using affinity chromatography, they identified a protein called LIMP-2 that binds to βGC with remarkable specificity. LIMP-2 is one of a number of transmembrane lysosomal resident proteins-such as LAMP-1 and LAMP-2-that are found in all cell types and are highly glycosylated on their luminal domains. LIMP-2 differs from LAMP-1 and LAMP-2 because it spans the membrane twice, with both N and C termini in the cytosol and a loop through the lumen of the lysosome. Reczek et al. show that βGC is recognized by LIMP-2 specifically and that in mice lacking LIMP-2, βGC is no longer sorted to lysosomes but is secreted. Proper lysosomal localization is restored by expression of LIMP-2, whereas expression of another lysosomal membrane protein, LAMP-2, had no effect. The authors map the site of interaction between βGC and LIMP-2 to a coiled-coil motif within the luminal loop of LIMP-2. Overexpression of a soluble form of this motif, which is itself secreted, results in enhanced secretion of βGC from cells.
Where in the cell does LIMP-2 recognize βGC? A number of results led the authors to suggest that recognition can occur in the endoplasmic reticulum (ER). First, they show that the association between the two proteins is pH dependent and is favored at the more neutral pH of the ER rather than the acidic pH of the lysosome. Second, they find that certain βGC mutants that are known to be retained in the ER can be shifted to the lysosome by overexpression of LIMP-2. Third, changing the carbohydrate modifications of LIMP-2, which are added after LIMP-2′s transit through the ER, had no effect on the association between LIMP-2 and βGC. The authors also show that addition of an ER-retention motif to LIMP-2 keeps βGC in this compartment. A simplified scheme of protein sorting to the lysosome that illustrates the differences between sorting of lysosomal hydrolases via the mannose 6-phosphate (M6P) receptor and the sorting of β-glucocerebrosidase (βGC) via LIMP-2. (Right) Newly synthesized βGC interacts with LIMP-2 in the endoplasmic reticulum (ER). Dissociation between LIMP-2 and βGC may only occur upon reaching the lysosome. Mutations in βGC that lead to loss of interaction with LIMP-2 can account for some cases of Gaucher disease. (Left) Lysosomal hydrolases interact with the M6P receptor in the trans-Golgi network. The M6P receptor is present on late endosomes but not lysosomes; lysosomal hydrolases are thought to dissociate from the receptor in late endosomes. Loss of phosphotransferase activity that adds the M6P to lysosomal hydrolases gives rise to I-cell disease (mucolipidosis type II).
The results from this new work are important not only because of the possible therapeutic implications for Gaucher disease but also because they highlight the fundamental difference between transport to lysosomes mediated by LIMP-2 and by the mannose 6-phosphate receptor (Figure 1) . Recognition of the mannose 6-phosphate carbohydrate modification on lysosomal hydrolases by the mannose 6-phosphate receptor occurs in the trans-Golgi network, whereas LIMP-2 recognition of βGC can take place in the ER and is apparently carbohydrate independent. Lysosomal hydrolases dissociate from the mannose 6-phosphate receptor in late endosomes as this receptor is not present in lysosomes, whereas LIMP-2 is present in lysosomes, suggesting that dissociation of βGC from LIMP-2 may occur in the lysosome itself. It is not clear whether LIMP-2 might mediate sorting of other proteins to the lysosome. It is also not clear whether LIMP-2 delivers newly synthesized proteins, endocytosed proteins, or both to lysosomes. However, the low levels of LIMP-2 found on the plasma membrane suggest that it may act primarily inside the cell.
These results provide yet another example of where the study of a lysosomal storage disease has provided insights into the fundamental mechanisms controlling protein sorting in cell biology. But what insights into Gaucher disease do these findings provide? One intriguing possibility raised by the authors is that some patients with Gaucher-like phenotypes might have mutations in LIMP-2 that might prevent proper sorting of βGC. Further studies of LIMP-2-deficient mice will certainly provide insights into this possibility. The current studies also open up new ways in which to understand the lossof-function mutations in βGC found in patients with Gaucher disease in terms of their recognition and transport by LIMP-2. Furthermore, by identifying the machinery that governs the secretion of βGC, these studies may provide ways to improve production of βGC, which is used therapeutically to treat patients with Gaucher disease. But perhaps most importantly these studies highlight the enormous synergy between studies of genetic diseases and our understanding of cell biology.
